Letter to the Editor: Immune-Mobilizing Monoclonal T-Cell Receptors: A Novel Addition in the HBV Armamentarium.

We read with interest the paper by Fergusson et al.1 Recent developments in HBV specific T-cell therapy, including dendritic cell vaccines, immune checkpoint inhibition, and adoptive cell transfer techniques, have yielded mixed results.2 However, this novel approach may become the way forward to address the shortcomings in previous strategies.